Pay in 4 interest-free payments of $5.44 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Tsiampali C, Papaioannidou P, Goulas A, Polyzos SA
Luo JC, Wu YL
Rare reports describe more significant reactions
spin-out built around Hengrui-licensed incretin assets - IPO'd in 2025 with HRS-4729 as part of a portfolio anchored on HRS9531 (a dual GLP-1/GIP agonist that read out ~17.7% weight loss in Phase 3 in China in February 2026)
Wolverine Research Applications Researchers across the globe study Wolverine for its potential applications in cellular biology, tissue engineering, regenerative medicine, and molecular signaling pathways
PMID: 25 Carreras-SuredaA.KroemerG.CardenasJ
US$ 28.14
US$ 20.68
US$ 28.39
US$ 25.75
US$ 25.55
US$ 25.42
US$ 23.53
US$ 25.18
US$ 28.17
US$ 22.82
US$ 28.54
US$ 23.86
